<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377139</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)54/2020</org_study_id>
    <nct_id>NCT04377139</nct_id>
  </id_info>
  <brief_title>Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)</brief_title>
  <official_title>Observational, Epidemiological, Retrospective Study of the Management of CMV Infection in a Cohort of Patients Receiving Lung Transplantation in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Lung transplant recipients (LTR) have the highest risk of CMV infection. CMV&#xD;
      pneumonitis, lymphocytic bronchitis, and detection of CMV DNA in bronchoalveolar lavage fluid&#xD;
      are independent risk factors for the development of chronic lung allograft dysfunction&#xD;
      (CLAD). However, to demonstrate the clinical impact of the indirect effects of CMV, it is&#xD;
      necessary to conduct studies with a very large sample size.&#xD;
&#xD;
      Hypothesis: The different current preventive strategies for CMV infection in LTR and their&#xD;
      clinical application on a daily basis impact on the development of direct and indirect&#xD;
      effects of CMV in this population.&#xD;
&#xD;
      Objectives: To study the effect of CMV infection on LTR in relation to current preventive&#xD;
      strategies in terms of:&#xD;
&#xD;
        -  The incidence of acute and chronic rejection&#xD;
&#xD;
        -  The incidence of other opportunistic infections&#xD;
&#xD;
        -  The incidence of neoplastic disease, especially, post-transplant lymphoproliferative&#xD;
           disease&#xD;
&#xD;
        -  Patient and graft survival Methods: Multicenter, retrospective, cohort study.&#xD;
           Consecutive inclusion of all adult lung transplant recipients from 2013 to 2017 with 2&#xD;
           years of follow-up. The investigators will collect and analyze the main clinical and&#xD;
           microbiological variables in order to respond to the objectives of the study.&#xD;
&#xD;
      Relevance: Knowing in detail the current epidemiology of CMV infection in LTR and its&#xD;
      subsequent influence on both mortality and the presence of different complications, could&#xD;
      allow improving the management of these patients in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CMV infection and/or disease</measure>
    <time_frame>Two-year follow-up</time_frame>
    <description>Incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft rejection both acute or CLAD</measure>
    <time_frame>Two-year follow-up</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Lung Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Prophylaxis</arm_group_label>
    <description>Those LTR receiving prophylaxis against CMV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preemptive therapy</arm_group_label>
    <description>Those LTR receiving preemptive therapy against CMV</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prophylaxis</intervention_name>
    <description>The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR</description>
    <arm_group_label>Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preemptive</intervention_name>
    <description>The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR</description>
    <arm_group_label>Preemptive therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All those LTR performed in Spain during the study period&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        · Survival &gt; 1 month post-transplant&#xD;
&#xD;
        • High to moderate risk patients to develop CMV disease by means of pre-transplant CMV&#xD;
        serology:&#xD;
&#xD;
          -  Donor positive to recipient negative&#xD;
&#xD;
          -  Recipient positive independently of donor serology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Survival &lt; 1 month after procedure&#xD;
&#xD;
          -  Low risk serology to develop CMV disease: both donor and recipient seronegative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oscar Len, MD</last_name>
    <phone>+34934896090</phone>
    <email>oscar.len@vhir.org</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytomegalovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

